Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 828,917 shares of the biopharmaceutical company's stock after selling 132,042 shares during the period. Legal & General Group Plc owned about 0.64% of Alnylam Pharmaceuticals worth $195,052,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of ALNY. Larson Financial Group LLC lifted its holdings in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 73 shares during the period. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Versant Capital Management Inc boosted its holdings in Alnylam Pharmaceuticals by 77.6% during the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 83 shares in the last quarter. Finally, IFP Advisors Inc increased its holdings in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In related news, Director Phillip A. Sharp sold 11,250 shares of the firm's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Down 3.2 %

Shares of NASDAQ:ALNY traded down $7.62 during trading on Tuesday, hitting $232.39. The company's stock had a trading volume of 266,552 shares, compared to its average volume of 863,076. The company has a market capitalization of $30.23 billion, a PE ratio of -107.09 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock's 50-day moving average price is $252.47 and its two-hundred day moving average price is $258.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Chardan Capital restated a "buy" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. Finally, Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.